Research programme: kynurenine pathway modulators - TES Pharma/Ecole Polytechnique Federale de Lausanne
Latest Information Update: 16 Jul 2015
At a glance
- Originator Ecole Polytechnique Federale de Lausanne.; Tes Pharma
- Class Small molecules
- Mechanism of Action Kynurenine modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Metabolic disorders
Most Recent Events
- 02 Jul 2015 Early research in Metabolic disorders in Italy and Switzerland (unspecified route)